Why Kintara Therapeutics Shares Are Gaining Today
Why Kintara Therapeutics Shares Are Gaining Today
Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares are trading higher in the premarket session on Wednesday with heavy volume.
Kintara Therapeutics, Inc.（納斯達克股票代碼：KTRA）股價在週三盤前交易中走高，成交量大。
The company entered into a definitive merger agreement with TuHURA Biosciences.
該公司與TuHura Biosciences簽訂了最終合併協議。
The combined company will focus on advancing TuHURA's personalized cancer vaccines and bi-functional ADCS. These two technologies seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer.
合併後的公司將專注於推進TuHura的個性化癌症疫苗和雙功能ADCS。這兩種技術旨在克服限制當前免疫療法治療癌症有效性的主要障礙。
The combined company is expected to operate under the name TuHURA Biosciences, Inc. and trade on the Nasdaq under the ticker "HURA."
預計合併後的公司將以TuHura Biosciences, Inc.的名義運營，並在納斯達克上市，股票代碼爲 “HURA”。
TuHURA plans to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda in first-line therapy for advanced Merkel cell carcinoma in the second half of 2024 under the FDA's accelerated approval pathway.
根據美國食品藥品管理局的加速批准途徑，TuHura計劃在2024年下半年推進一項將iFX-2.0個性化癌症疫苗作爲輔助療法的單一3期試驗，用於晚期默克爾細胞癌的一線治療。
"Coupled with a $31 million subscribed financing by TuHURA in connection with the merger agreement, and which is expected to fund the combined company's operations and development programs through late 2025, we believe this merger will also allow our combined company the flexibility to focus our resources and efforts on advancing IFx-2.0 to market and our other drug candidates toward human clinical trials," said Dr. James Bianco, President and Chief Executive Officer of TuHURA.
TuHura總裁兼首席執行官詹姆斯·比安科博士表示：“再加上TuHura認購的與合併協議相關的3,100萬美元融資，預計將在2025年底之前爲合併後的公司的運營和發展計劃提供資金，我們相信此次合併還將使合併後的公司能夠靈活地將資源和精力集中在將iFX-2.0推向市場以及將其他候選藥物推向人體臨床試驗上。”
Subject to shareholder approval, post-merger, Kintara equityholders are set to collectively own around 2.85% of the combined company's common stock, or approximately 5.45% including CVR shares.
經股東批准，合併後，Kintara股權持有人將集體擁有合併後公司普通股約2.85％，包括CVR股票在內的約5.45％。
TuHURA equityholders are expected to hold approximately 97.15% of the common stock, or 94.55% with CVR shares distributed.
預計TuHura股東將持有約97.15％的普通股，分配CVR股票後將佔94.55％。
Price Action: KTRA shares are trading higher by 129% to $0.23 premarket on the last check Wednesday.
價格走勢：在週三的最後一次支票中，KTRA股價盤前上漲129％，至0.23美元。
Illustration of Phrama lab worker created with MidJourney.
使用 MidJourney 創作的 Phrama 實驗室工作人員的插圖。
譯文內容由第三人軟體翻譯。